Metabolic disorders in menopause

Metabolic disorders occurring in menopause, including dyslipidemia, disorders of carbohydrate metabolism (impaired glucose tolerance – IGT, type 2 diabetes mellitus – T2DM) or components of metabolic syndrome, constitute risk factors for cardiovascular disease in women. A key role could be played he...

Full description

Bibliographic Details
Main Authors: Grzegorz Stachowiak, Tomasz Pertyński, Magdalena Pertyńska-Marczewska
Format: Article
Language:English
Published: Termedia Publishing House 2015-04-01
Series:Menopause Review
Subjects:
Online Access:http://www.termedia.pl/Metabolic-disorders-in-menopause,4,24871,1,1.html
id doaj-9b96ee80a38b43afa70282247e80cdd2
record_format Article
spelling doaj-9b96ee80a38b43afa70282247e80cdd22020-11-24T23:36:19ZengTermedia Publishing HouseMenopause Review1643-88762299-00382015-04-01141596410.5114/pm.2015.5000024871Metabolic disorders in menopauseGrzegorz StachowiakTomasz PertyńskiMagdalena Pertyńska-MarczewskaMetabolic disorders occurring in menopause, including dyslipidemia, disorders of carbohydrate metabolism (impaired glucose tolerance – IGT, type 2 diabetes mellitus – T2DM) or components of metabolic syndrome, constitute risk factors for cardiovascular disease in women. A key role could be played here by hyperinsulinemia, insulin resistance and visceral obesity, all contributing to dyslipidemia, oxidative stress, inflammation, alter coagulation and atherosclerosis observed during the menopausal period. Undiagnosed and untreated, metabolic disorders may adversely affect the length and quality of women’s life. Prevention and treatment preceded by early diagnosis should be the main goal for the physicians involved in menopausal care. This article represents a short review of the current knowledge concerning metabolic disorders (e.g. obesity, polycystic ovary syndrome or thyroid diseases) in menopause, including the role of a tailored menopausal hormone therapy (HT). According to current data, HT is not recommend as a preventive strategy for metabolic disorders in menopause. Nevertheless, as part of a comprehensive strategy to prevent chronic diseases after menopause, menopausal hormone therapy, particularly estrogen therapy may be considered (after balancing benefits/risks and excluding women with absolute contraindications to this therapy). Life-style modifications, with moderate physical activity and healthy diet at the forefront, should be still the first choice recommendation for all patients with menopausal metabolic abnormalities.http://www.termedia.pl/Metabolic-disorders-in-menopause,4,24871,1,1.htmlmenopause insulin resistance diabetes metabolic syndrome PCOS
collection DOAJ
language English
format Article
sources DOAJ
author Grzegorz Stachowiak
Tomasz Pertyński
Magdalena Pertyńska-Marczewska
spellingShingle Grzegorz Stachowiak
Tomasz Pertyński
Magdalena Pertyńska-Marczewska
Metabolic disorders in menopause
Menopause Review
menopause
insulin resistance
diabetes
metabolic syndrome
PCOS
author_facet Grzegorz Stachowiak
Tomasz Pertyński
Magdalena Pertyńska-Marczewska
author_sort Grzegorz Stachowiak
title Metabolic disorders in menopause
title_short Metabolic disorders in menopause
title_full Metabolic disorders in menopause
title_fullStr Metabolic disorders in menopause
title_full_unstemmed Metabolic disorders in menopause
title_sort metabolic disorders in menopause
publisher Termedia Publishing House
series Menopause Review
issn 1643-8876
2299-0038
publishDate 2015-04-01
description Metabolic disorders occurring in menopause, including dyslipidemia, disorders of carbohydrate metabolism (impaired glucose tolerance – IGT, type 2 diabetes mellitus – T2DM) or components of metabolic syndrome, constitute risk factors for cardiovascular disease in women. A key role could be played here by hyperinsulinemia, insulin resistance and visceral obesity, all contributing to dyslipidemia, oxidative stress, inflammation, alter coagulation and atherosclerosis observed during the menopausal period. Undiagnosed and untreated, metabolic disorders may adversely affect the length and quality of women’s life. Prevention and treatment preceded by early diagnosis should be the main goal for the physicians involved in menopausal care. This article represents a short review of the current knowledge concerning metabolic disorders (e.g. obesity, polycystic ovary syndrome or thyroid diseases) in menopause, including the role of a tailored menopausal hormone therapy (HT). According to current data, HT is not recommend as a preventive strategy for metabolic disorders in menopause. Nevertheless, as part of a comprehensive strategy to prevent chronic diseases after menopause, menopausal hormone therapy, particularly estrogen therapy may be considered (after balancing benefits/risks and excluding women with absolute contraindications to this therapy). Life-style modifications, with moderate physical activity and healthy diet at the forefront, should be still the first choice recommendation for all patients with menopausal metabolic abnormalities.
topic menopause
insulin resistance
diabetes
metabolic syndrome
PCOS
url http://www.termedia.pl/Metabolic-disorders-in-menopause,4,24871,1,1.html
work_keys_str_mv AT grzegorzstachowiak metabolicdisordersinmenopause
AT tomaszpertynski metabolicdisordersinmenopause
AT magdalenapertynskamarczewska metabolicdisordersinmenopause
_version_ 1725524117799567360